Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, Baglin A
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
1 The pharmacokinetics of atenolol, after 200 mg orally, were studied in 18 patients with terminal renal insufficiency (creatinine clearance less than 5 ml/min), of whom twelve were being treated by chronic dialysis. 2 The peak plasma level, 1.59 +/- 0.43 mg/l, was reached in 4.7 +/- 2.1 h. 3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73.4 +/- 28.8 /). During dialysis, it dropped to 7.5 +/- 3.7 h but returned to 51.2 +/- 17.3 h after dialysis. The plasma atenolol plot was a rising slope for a few hours after the end of dialysis. 4 Renal clearance of atenolol was very low (4.6 +/- 1.5 ml/min). 5 Plasma clearance during dialysis was 42.6 +/- 21.3 ml/min for a mean blood flow-rate of 236 +/- 25 ml/min through a cuprophane membrane dialyser. 6 These results suggest that dosage should be modified for these patients.
对18例终末期肾功能不全(肌酐清除率低于5ml/min)患者口服200mg阿替洛尔后的药代动力学进行了研究,其中12例患者正在接受慢性透析治疗。
血浆峰值水平为1.59±0.43mg/l,在4.7±2.1小时达到。
未进行透析治疗时,阿替洛尔的表观血浆半衰期大大延长(73.4±28.8小时)。透析期间,半衰期降至7.5±3.7小时,但透析后又回升至51.2±17.3小时。透析结束后数小时内,血浆阿替洛尔曲线呈上升斜率。
阿替洛尔的肾清除率非常低(4.6±1.5ml/min)。
通过铜仿膜透析器,平均血流速率为236±25ml/min时,透析期间的血浆清除率为42.6±21.3ml/min。
这些结果表明,应对这些患者调整剂量。